Cantor Fitzgerald Issues Positive Forecast for VNDA Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for Vanda Pharmaceuticals in a report released on Thursday, October 30th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will earn ($1.87) per share for the year, up from their prior estimate of ($2.03). Cantor Fitzgerald has a “Overweight” rating and a $11.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. Cantor Fitzgerald also issued estimates for Vanda Pharmaceuticals’ FY2026 earnings at ($2.42) EPS.

A number of other brokerages also recently issued reports on VNDA. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Thursday, August 21st. Wall Street Zen raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vanda Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $15.50.

Vanda Pharmaceuticals Stock Down 2.7%

NASDAQ:VNDA opened at $4.35 on Monday. Vanda Pharmaceuticals has a 52 week low of $3.81 and a 52 week high of $5.70. The stock’s 50-day moving average price is $4.93 and its 200-day moving average price is $4.65. The stock has a market capitalization of $257.04 million, a PE ratio of -3.06 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The firm had revenue of $56.26 million during the quarter, compared to analysts’ expectations of $58.73 million. Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.44%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC lifted its holdings in Vanda Pharmaceuticals by 424.6% during the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 7,575 shares in the last quarter. PVG Asset Management Corp purchased a new position in Vanda Pharmaceuticals during the first quarter valued at $48,000. Linden Thomas Advisory Services LLC purchased a new position in Vanda Pharmaceuticals during the first quarter valued at $49,000. Nations Financial Group Inc. IA ADV acquired a new stake in shares of Vanda Pharmaceuticals in the first quarter valued at about $67,000. Finally, Cerity Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at about $69,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.